Understanding the Philosophy, Anatomy, and Surgery of the Extra-TME Plane of Locally Advanced and Locally Recurrent Rectal Cancer; Single Institution Experience with International Benchmarking

被引:18
作者
van Kessel, Charlotte S. [1 ,2 ]
Solomon, Michael J. [1 ,2 ,3 ,4 ]
机构
[1] Royal Prince Alfred Hosp, Surg Outcomes Res Ctr SOuRCe, Sydney, NSW 2050, Australia
[2] Royal Prince Alfred Hosp, Dept Colorectal Surg, Sydney, NSW 2050, Australia
[3] RPA, Inst Acad Surg, Sydney, NSW 2050, Australia
[4] Univ Sydney, Fac Med & Hlth, Sydney, NSW 2006, Australia
关键词
pelvic exenteration; locally advanced and recurrent rectal cancer; pelvic compartments; radical surgery; R0; resection; neoadjuvant treatment; TOTAL MESORECTAL EXCISION; PELVIC EXENTERATION; SACRAL RESECTION; PREOPERATIVE RADIOTHERAPY; SURVIVAL; OUTCOMES; IMPACT; CHEMORADIOTHERAPY; MANAGEMENT; MORBIDITY;
D O I
10.3390/cancers14205058
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Worldwide there is still unwarranted variation in peri-operative management and subsequently oncological outcome following pelvic exenteration for locally advanced and recurrent rectal cancer. The major contributing factor seems to be a difference in treatment strategy with many centres aiming for more neoadjuvant treatment and less radical surgery. However, a radical resection with clear operative margins remains the single most important prognostic factor for survival and therefore an aggressive, radical approach is justified for an optimal oncological outcome and remains the gold standard of care. Pelvic exenteration surgery has become a widely accepted procedure for treatment of locally advanced (LARC) and locally recurrent rectal cancer (LRRC). However, there is still unwarranted variation in peri-operative management and subsequently oncological outcome after this procedure. In this article we will elaborate on the various reasons for the observed differences based on benchmarking results of our own data to the data from the PelvEx collaborative as well as findings from 2 other benchmarking studies. Our main observation was a significant difference in extent of resection between exenteration units, with our unit performing more complete soft tissue exenterations, sacrectomies and extended lateral compartment resections than most other units, resulting in a higher R0 rate and longer overall survival. Secondly, current literature shows there is a tendency to use more neoadjuvant treatment such as re-irradiation and total neoadjuvant treatment and perform less radical surgery. However, peri-operative chemotherapy or radiotherapy should not be a substitute for adequate radical surgery and an R0 resection remains the gold standard. Finally, we describe our experiences with standardizing our surgical approaches to the various compartments and the achieved oncological and functional outcomes.
引用
收藏
页数:15
相关论文
共 50 条
[41]   Robotic Surgery of Locally Advanced Gastric Cancer: A Single-Surgeon Experience of 41 Cases [J].
Vasilescu, C. ;
Procopiuc, L. .
CHIRURGIA, 2012, 107 (04) :510-517
[42]   Risk factors for early complications after laparoscopic total mesorectal excision for locally advanced rectal cancer: A single center experience [J].
Liu, Liye ;
Wang, Tao ;
Zhang, Guohu ;
Dai, Ruiwu ;
Liang, Hongyin ;
Tang, Lijun .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) :350-354
[43]   Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy: results from a single institution [J].
Khalil, J. ;
El Kacemi, H. ;
Afif, M. ;
Kebdani, T. ;
Benjaafar, N. .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2015, 292 (05) :1091-1099
[44]   Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution [J].
Atallah, S. ;
Martin-Perez, B. ;
Albert, M. ;
deBeche-Adams, T. ;
Nassif, G. ;
Hunter, L. ;
Larach, S. .
TECHNIQUES IN COLOPROCTOLOGY, 2014, 18 (05) :473-480
[45]   Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age [J].
Larsen, SG ;
Wiig, JN ;
Tretli, S ;
Giercksky, KE .
COLORECTAL DISEASE, 2006, 8 (03) :177-185
[46]   Image-Guided versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period [J].
Lee, Tae Hoon ;
Kim, Kyung Su ;
Kim, Hak Jae ;
Choi, Chang Heon ;
Kang, Seonghee ;
Eom, Keun-Yong ;
Wee, Chan Woo ;
Song, Yong Sang ;
Park, Noh Hyun ;
Kim, Jae-Weon ;
Chung, Hyun Hoon ;
Kim, Hee Seung ;
Lee, Maria ;
Kang, Hyun-Cheol .
CANCER RESEARCH AND TREATMENT, 2023, 55 (01) :258-269
[47]   Outcomes Following Surgery for Locally Advanced Pancreatic Cancer - Single Center Experience. A Retrospective Study [J].
Filip, Bogdan ;
Scripcariu, Dragos ;
Hutanu, Ionut ;
Radu, Iulian ;
Gavrilescu, Madalina ;
Scripcariu, Viorel .
CHIRURGIA, 2022, 117 (04) :447-453
[48]   Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience [J].
Guo, Susan ;
Reddy, Chandana A. ;
Kolar, Matthew ;
Woody, Neil ;
Mahadevan, Arul ;
Deibel, F. Christopher ;
Dietz, David W. ;
Remzi, Feza H. ;
Suh, John H. .
RADIATION ONCOLOGY, 2012, 7
[49]   Initial experience and results of robotic lateral pelvic lymph node dissection in locally advanced rectal cancer-a single center experience of 17 consecutive procedures [J].
Eriksen, Jens Ravn ;
Brisling, Steffen Kirstein ;
Gogenur, Ismail .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2024, 39 (01)
[50]   Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma? A Single-Institution Experience [J].
Phuong Nguyen ;
Wuthrick, Evan ;
Chablani, Priyanka ;
Robinson, Andrew ;
Simmons, Luke ;
Wu, Christina ;
Arnold, Mark ;
Harzman, Alan E. ;
Husain, Syed ;
Schmidt, Carl ;
Abdel-Misih, Sherif ;
Bekaii-Saab, Tanios ;
Chakravarti, Arnab ;
Williams, Terence M. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (02) :140-146